Palvella Therapeutics (PVLA) Non Operating Income (2015 - 2024)
Palvella Therapeutics' (PVLA) quarterly Non Operating Income came in at $169000.0 in Q3 2024, down 69.22% year-on-year from $549000.0 in Q4 2023, and down 15.92% on a QoQ basis from $201000.0 in Q2 2024.
Palvella Therapeutics (PVLA) Non Operating Income (2015 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has 9 years of Non Operating Income data on file, last reported at $169000.0 in Q3 2024.
- On a quarterly basis, Non Operating Income fell 69.22% year-over-year to $169000.0 in Q3 2024; TTM through Sep 2024 was $1.1 million, a 39.04% decrease from a year earlier, with the FY2023 full-year figure at $1.9 million, up 156.73% from the prior year.
- Non Operating Income for Q3 2024 stood at $169000.0, down from $201000.0 in the prior quarter.
- Over the last five years, Non Operating Income for PVLA reached as high as $549000.0 in Q3 2023 and fell as low as -$6000.0 in Q4 2021.
- Historically, Non Operating Income has averaged $194578.9 across 5 years, with a median of $169000.0 in 2024.
- Across the five-year window, Non Operating Income slumped 200.0% in 2022 and surged 12000.0% in 2023, its largest moves.
- Year by year, Non Operating Income stood at $8000.0 in 2020, then sank by 175.0% to -$6000.0 in 2021, then jumped by 5950.0% to $351000.0 in 2022, then grew by 29.63% to $455000.0 in 2023, then tumbled by 62.86% to $169000.0 in 2024.
- Per Business Quant data, the three most recent Non Operating Income figures were $169000.0 in Q3 2024, $201000.0 in Q2 2024, and $240000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | Palvella Therapeutics | 1.84 Bn | 1.57 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 169,000.00 |
| Jun 30, 2024 | 201,000.00 |
| Mar 31, 2024 | 240,000.00 |
| Dec 31, 2023 | 455,000.00 |
| Sep 30, 2023 | 549,000.00 |
| Jun 30, 2023 | 490,000.00 |
| Mar 31, 2023 | 357,000.00 |
| Dec 31, 2022 | 351,000.00 |
| Sep 30, 2022 | 241,000.00 |
| Jun 30, 2022 | 132,000.00 |
| Mar 31, 2022 | -3,000.00 |
| Dec 31, 2021 | -6,000.00 |
| Sep 30, 2021 | 4,000.00 |
| Jun 30, 2021 | 3,000.00 |
| Mar 31, 2021 | 3,000.00 |
| Dec 31, 2020 | 8,000.00 |
| Sep 30, 2020 | 55,000.00 |
| Jun 30, 2020 | 129,000.00 |
| Mar 31, 2020 | 319,000.00 |
| Dec 31, 2019 | 382,000.00 |